SkinBioTherapeutics plc (SBTX) Ord GBP0.01
![](https://online.hl.co.uk/img/hl/layout/security-down-arrow.gif)
- Add to watchlist
- Create an alert
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-down-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-down-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Share news, reports & tips
-
SkinBioTherapeutics reports positive interim acne study findings
27 February 2024 15:44
(Sharecast News) - Life science company SkinBioTherapeutics reported encouraging interim findings from its ongoing AxisBiotix acne food supplement study featuring its lead formulation on Tuesday.
-
SkinBioTherapeutics finalises acquisition of Dermatronics
26 January 2024 16:04
(Sharecast News) - SkinBioTherapeutics announced on Friday that it has finalised the acquisition of Dermatonics, known for its topical and dermatological products within the skincare and wound care sector.
-
SkinBioTherapeutics launches new consumer study into acne
25 October 2023 09:08
(Sharecast News) - Life sciences company SkinBioTherapeutics said on Wednesday that it had begun a new consumer study into acne, with two new formulas set to be trialled in order to compare efficacy against...
-
SkinBioTherapeutics gets France approval for psoriasis supplement
15 September 2023 10:11
(Sharecast News) - SkinBioTherapeutics has been given the green light by French regulators to introduce its food supplement, AxisBiotix-Ps, into the French market, it announced on Friday.
-
SkinBioTherapeutics selects probiotic blends for acne study
5 September 2023 12:44
(Sharecast News) - Skin health specialist SkinBioTherapeutics updated the market on its decision on the probiotic blends to be used in a consumer volunteer study aimed at acne treatment on Tuesday.
-
SkinBioTherapeutics launching psoriasis supplement in Italy
21 June 2023 17:00
(Sharecast News) - Skin health specialist SkinBioTherapeutics has received regulatory approval to introduce 'AxisBiotix-Ps' - a food supplement designed to alleviate the symptoms associated with...
-
SkinBioTherapeutics pleased with progress on two fronts
10 May 2023 13:05
(Sharecast News) - Skin health-focussed life science company SkinBioTherapeutics said in an update on Wednesday that its partner Sederma, a division of Croda International, was planning to undertake...
-
SkinBioTherapeutics reports progress with psoriasis supplement roll-out
17 February 2022 15:34
(Sharecast News) - SkinBioTherapeutics updated the market on Thursday on the commercialisation of its food supplement product 'AxisBiotix-Ps', designed for the symptoms of psoriasis.
-
SkinBioTherapeutics commercially launches psoriasis supplement
29 October 2021 12:48
(Sharecast News) - Skin health-focussed life sciences company SkinBioTherapeutics announced the commercial launch of 'AxisBiotix-Ps' on Friday, which it described as a probiotic food supplement to...
-
SkinBioTherapeutics confirms launch plans for psoriasis supplement
30 September 2021 15:38
(Sharecast News) - Skin health-focussed life science company SkinBioTherapeutics updated the market on its commercialisation plans for 'AxisBiotix-Ps' on Thursday, which it described as its...
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.